Repeat PSMA PET scans change treatment for half of prostate cancer patients

A recent study published in the July issue of *The Journal of Nuclear Medicine* reports that a second prostate‑specific membrane antigen (PSMA) positron emission tomography (PET) scan altered the treatment strategy for almost half of patients whose initial scan was negative. The research evaluated repeat PSMA PET imaging in patients with both local and distant prostate cancer and found that nearly 50 % experienced a change in management, ranging from surgical planning to systemic therapy adjustments.

The findings underscore the sensitivity of PSMA PET for detecting occult disease that may be missed on a first scan. By revealing additional lesions or confirming disease spread, the repeat imaging prompted clinicians to modify treatment approaches, potentially improving disease control and patient outcomes. The study suggests that incorporating a second PSMA PET scan into the diagnostic workflow could provide a more comprehensive assessment of prostate cancer extent.

These results may influence future guidelines for prostate cancer imaging, encouraging clinicians to consider repeat PSMA PET scans when initial studies are negative but clinical suspicion remains high. The data highlight the evolving role of advanced molecular imaging in tailoring individualized treatment plans for prostate cancer patients.